ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm

by Anumana, Inc.  · Based in United States → — Unlocking the Language of the Heart
Cardiology Hospital Medicine Internal Medicine

Regulatory Status Disclosed

Overview

The Anumana ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm is a software as a medical device (SaMD) designed to assist clinicians in identifying adult patients who may be at risk for Cardiac Amyloidosis (CA) using a standard 12-lead electrocardiogram (ECG).

  • What it does:This AI-enabled algorithm analyzes ECG waveforms to detect patterns associated with CA that may not be apparent through human interpretation. It is intended to aid in earlier detection of CA in adults being evaluated for signs or symptoms consistent with the condition, including those with unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, or aortic stenosis.
  • Who it is for:The tool is relevant for various specialties and care settings where patients are evaluated for cardiac symptoms, particularly those with comorbidities associated with CA. This includes cardiologists, primary care physicians, and other clinicians in hospital or outpatient settings.
  • How it fits a clinical or practice workflow:The algorithm integrates into existing clinical workflows by utilizing standard 12-lead ECGs that are routinely obtained in practice, without requiring additional testing. It is not intended as a standalone diagnostic tool but rather to support clinicians in identifying patients who may benefit from further evaluation for CA.
  • Notable capabilities:The ECG-AI CA algorithm was developed at Mayo Clinic and validated in a multi-center study.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven analysis of standard 12-lead ECGs
  • Detects cardiac disease signals invisible to the human eye
  • Integrates with existing clinical workflows and EHRs
  • Aids in earlier detection of Cardiac Amyloidosis
  • Software as a Medical Device (SaMD)
  • Clinically validated with extensive evidence base
  • Supports clinical decision-making at the point of care
  • Eligible for reimbursement

Use Cases

  • Early identification of cardiac amyloidosis in adults being evaluated for consistent signs or symptoms
  • Screening patients with conditions commonly associated with cardiac amyloidosis (e.g., unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, aortic stenosis)
  • Supporting clinicians in recognizing suspicion of cardiac amyloidosis from routine ECGs
  • Guiding further clinical evaluation for at-risk patients

What Physicians Need to Know

ECG/EKG Analysis Capability
The ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm is a software as a medical device (SaMD) that analyzes standard 12-lead ECGs to aid in the earlier detection of Cardiac Amyloidosis in adults. It uses a deep learning model to identify subtle patterns in ECG waveforms that may indicate CA, which can be missed by human interpretation. The algorithm has shown an area under the receiver operating characteristic curve (AUC) of 0.91 for detecting CA. It can also work with single-lead and 6-lead ECG applications, although with slightly lower performance.
Heart Failure Risk Prediction
The algorithm aids in the earlier detection of Cardiac Amyloidosis, a condition that can lead to heart failure if not recognized early. By identifying CA, the tool indirectly contributes to heart failure risk prediction and management, as early diagnosis allows for timely intervention and improved outcomes. The AI-enhanced ECG model (A2E) has also been shown to be independently prognostic for overall survival in both AL and ATTR CA, suggesting its utility in risk stratification.
AHA/ACC Guideline Alignment
The ECG-AI Cardiac Amyloidosis 12-Lead Algorithm is not intended to replace current clinical practice guidelines but rather to aid in earlier detection. A positive result suggests the need for further clinical evaluation to establish a diagnosis of Cardiac Amyloidosis, aligning with a guideline-driven diagnostic pathway.
Real-Time Alert Capability
The algorithm is designed to help clinicians identify patients who may be at risk for CA at the point of care, suggesting a capability to provide timely information. This can support earlier diagnosis and more timely next steps in care.
Physician Tip

This AI-powered ECG algorithm serves as a valuable screening tool to flag patients at risk for cardiac amyloidosis, especially those with non-specific symptoms or comorbidities like unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, or aortic stenosis. A positive result warrants further clinical evaluation, but a negative result in a high-risk patient should not rule out additional investigation. It's crucial to integrate this tool with clinical judgment and existing guidelines, as it is not a stand-alone diagnostic device. The ability to detect CA earlier, even before advanced imaging, can significantly impact patient outcomes by enabling timely interventions.

The ECG-AI Cardiac Amyloidosis 12-Lead Algorithm is designed as a software-as-a-medical-device (SaMD) that integrates into existing clinical workflows by analyzing standard 12-lead ECG data already gathered in practice, without requiring additional testing. It is built on a secure, clinically validated infrastructure to support seamless integration across diverse healthcare systems. The algorithm was developed in collaboration with Mayo Clinic and has been validated in large, independent, multi-center studies across various U.S. health systems. Anumana is actively pursuing regulatory approval for this algorithm in the USA, Europe, and Japan.

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Unknown
DeploymentIntegrated with existing ECG management systems and EHR environments
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Cardiology, Hospital Medicine, Internal Medicine

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm.

Loading videos...

View all on YouTube

Frequently Asked Questions

The ECG-AI Cardiac Amyloidosis 12-Lead Algorithm is a software as a medical device (SaMD) that analyzes standard 12-lead ECGs to identify subtle patterns indicative of cardiac amyloidosis (CA). It is intended to aid in the earlier detection of CA in adults who are being evaluated for signs or symptoms consistent with the condition, such as unexplained heart failure, nephrotic syndrome, peripheral neuropathy, arrhythmias, or aortic stenosis.
The ECG-AI Cardiac Amyloidosis algorithm has received U.S. Food and Drug Administration (FDA) clearance, making it the first and only device cleared for this indication using standard 12-lead ECGs. It was initially developed at Mayo Clinic and subsequently validated in a large, independent, multi-center study of 25,525 patients across four U.S. health systems, demonstrating 78.9% sensitivity and 91.2% specificity in adult patients with signs, symptoms, or comorbidities of CA.
This algorithm is not intended to be a standalone diagnostic device for cardiac amyloidosis, nor does it replace current clinical practice guidelines. A positive result suggests the need for further clinical evaluation, and a negative result in a high-risk patient should not rule out additional clinical evaluation. The algorithm's performance may be lower in patients with left bundle branch block, left ventricular hypertrophy, and ethnically diverse populations, emphasizing the need for subgroup-specific validation.
While the Anumana ECG-AI algorithm is the first FDA-cleared for CA using standard 12-lead ECGs, other AI algorithms for standard 12-lead ECGs have been developed with comparable diagnostic accuracy. Additionally, some research explores 3-dimensional ECG algorithms using fewer leads for screening. Current diagnostic modalities also include advanced imaging techniques like cardiac MRI and radionuclide imaging, and sometimes invasive myocardial biopsy.
The ECG-AI algorithm is designed to integrate into existing workflows by analyzing ECG data already gathered in clinical practice, without requiring additional testing. It is intended to be applied jointly with clinician judgment, providing decision support and potentially flagging patients at risk who might otherwise not be evaluated further. Compliance would involve adhering to the indications for use, recognizing it as an aid for earlier detection, and not a standalone diagnostic tool.
Early diagnosis of cardiac amyloidosis is critical, as timely intervention can significantly improve patient outcomes. By aiding in earlier detection, the algorithm may lead to more efficient use of confirmatory testing and earlier initiation of treatment. While specific pricing for the CA algorithm isn't detailed, similar AI-ECG programs for other conditions have shown to be cost-effective.

Related Tools

Exo Iris
Exo Imaging, Inc.
Cardiology AI
PanEcho
Yale School of Medicine (Cardiovascular Data Science Lab)
Cardiology AI
PanEcho is an AI tool from Yale School of Medicine that interprets echocardiograms with high accuracy, performing 39 diagnostic tasks and detecting conditions like severe aortic stenosis and systolic dysfunction.
Hexoskin Medical
Hexoskin
Cardiology AI
EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.

See all Cardiology AI tools →

More from Anumana

ECG-AI Pulmonary Hypertension (PH) 12-Lead algorithm
Anumana
Cardiology AI
An AI algorithm that analyzes standard 12-lead ECG recordings to detect signs of pulmonary hypertension, aiming for earlier diagnosis and improved patient outcomes.
Low Ejection Fraction AI-ECG Algorithm
Anumana
Cardiology AI
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-09-23 | First Added: 2026-09-23
AI Tool Finder
AI-powered search. Results may not be comprehensive.